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ABSTRACT Cyclooxygenase (COX) -1 and COX-2
are expressed in airway cells, where their activities
influence functions such as airway hyperreactivity. Clin-
ical data show that mixed COX-1/COX-2 inhibitors
such as aspirin, but not COX-2 selective inhibitors such
as rofecoxib, induce bronchoconstriction and asthma
in sensitive individuals. This anomaly has not yet been
explained. Here, we have used tissue from genetically
modified mice lacking functional COX-1 (COX-1/),
as well as airway tissue from “aspirin-sensitive” and
control patients to address this issue. Bronchi from
wild-type mice contained predominantly COX-1 immu-
noreactivity and contracted in vitro in response to
acetylcholine and U46619. Bronchi from COX-1/
mice were hyperresponsive to bronchoconstrictors. In-
hibitors of COX (naproxen, diclofenac, or ibuprofen)
increased bronchoconstriction in tissue from wild-type
but not from COX-1/ mice. Cells cultured from
aspirin-sensitive or control human donors contained
similar levels of COX-1 and COX-2 immunoreactivity.
COX activity in cells from aspirin-sensitive or tolerant
patients was inhibited by aspirin, SC560, which blocks
COX-1 selectively, but not by rofecoxib, which is a
selective inhibitor of COX-2. These observations show
that despite the presence of COX-2, COX-1 is function-
ally predominant in the airways and explains clinical
observations relating to drug specificity in patients with
aspirin-sensitive asthma.—Harrington, L. S., Lucas, R.,
McMaster, S. K., Moreno, L., Scadding, G., Warner,
T. D., Mitchell, J. A. COX-1, and not COX-2 activity,
regulates airway function: relevance to aspirin-sensitive
asthma. FASEB J. 22, 4005–4010 (2008)
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Cyclooxygenase (COX) -1 and COX-2 are coex-
pressed in the airways of healthy individuals, as well
as in patients with asthma (1). Inhibition of COX
enhances bronchoconstriction in mice (2). Further-
more, in a subgroup of patients with asthma, aspirin
or other nonsteroidal anti-inflammatory drugs
(NSAIDs) induce bronchoconstriction and acute
asthma, resulting in the “aspirin-sensitive asthma”
condition (3). It is thought that prostaglandin (PG)
E2, a product of COX, acts on prostaglandin E (EP)
receptors on mast cells in the airways, providing a
physiological brake against activation and histamine/
leukotriene release (4). Thus, when aspirin and
other NSAIDs are taken, COX is inhibited, the brake
is removed, and airways are hypersensitive to anti-
gens. Asthma is a chronic inflammatory disease in
which COX-2 levels within the lung are elevated (5).
Interestingly, despite COX-2 being present in the
lung, COX-2 selective drugs, such as rofecoxib
(Vioxx), do not induce asthma in these patients (6).
This then presents the field with an anomaly—why do
COX-2-selective drugs not induce asthma?
In the current study, we present novel and meaning-
ful data that shed light on this important area. First,
using tissue from COX-1/ mice, we show that COX-1
is the functional isoform present in the airway with
regard to bronchoconstriction. Second, using cells cul-
tured from the airways of patients with aspirin-sensitive
asthma, we show that despite detectable levels of
COX-2, COX-1 is the functionally relevant form. Taken
together, these observations provide a scientific ratio-
nale as to why COX-2 inhibitors are safe in asthma and
illustrates a remarkably clear cut function of COX-1 in
airway function.
MATERIALS AND METHODS
Mice and myograph studies
The COX-1/ mice used in this study had an insertion into
intron 11, resulting in transcription of an inactive “COX-1”
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protein (7). COX-1/ mice were backcrossed for more
than 7 generations onto a C57BL6 background. C57BL6
mice were used as wild-type controls. Male mice of 12–16
wk of age were used for this study. Mice were killed by
cervical dislocation, before lungs were removed and dis-
sected clear of connective tissue. Segments of main bron-
chi were loaded into wire myographs in warmed (37°C)
and gassed (95%O2:5%CO2) physiological salt solution
(PSS; NaCl, 119 mM; KCl, 4.7 mM; CaCl2, 2.5 mM; MgSO4,
1.17 mM; NaHCO3, 25 mM; KH2PO4, 1.18 mM; EDTA,
0.027 mM; and glucose, 5.5 mM), as described previously
(8). Isometric tension was initially calibrated to 0 mN.
Optimal tensions for each bronchus were established by
performing standard-length tension responses. In brief,
bronchi were sequentially stretched by 0.25-mN increments
(passive tension) and stimulated to contract actively (active
tension) by the additions of a depolarizing concentration
of potassium (124 mM). Optimal tension was taken at the
point at which increased stretch ceased to increase active
tension. Bronchi were then allowed to equilibrate for 20
min in PSS. Tissues were subjected to increasing concen-
trations of either acetylcholine or U46619, and tensions
were recorded. In some experiments, NSAIDs or vehicle
(dimethyl sulfoxide) were added for 30 min prior to the
addition of acetylcholine or U46619.
Human tissue
All subjects in the aspirin-sensitive asthma group had a
history of aspirin-induced reaction, in that they developed
a respiratory-type reaction following aspirin or NSAID
ingestion. The reactions included bronchospasm, cough-
ing, wheezing, and shortness of breath, as well as upper
airway symptoms of rhinorrhoea and nasal obstruction.
These patients had their aspirin sensitivity confirmed by an
intranasal challenge with lysine-aspirin, as we have described
previously (9). All patients (except for one) were receiving
regular inhaled corticosteroids and 2 adrenoreceptor
stimulants, for use as required. Nasal polyp tissue was
removed as part of outpatient surgery, as we have described
previously (10). Tissue was dissected to remove the core
inflammatory cell component, which is easily dissociated
from surrounding stromal tissue and consists of inflamma-
tory cells, including leukocytes and mast cells. Once the
inflammatory core was removed the stromal airway tissue
was chopped into small pieces and placed in to culture
flasks containing DMEM supplemented with penicillin-
streptomycin and 10% fetal calf serum. Cells began to grow
out of the explants after 2–3 wk. Cells were fibroblast-like
in appearance. Cells were plated into individual wells of
either 96- or 6-well culture plates and grown in supple-
mented medium until confluent. For some experiments,
cells were incubated with interleukin 1 (IL-1; 1 ng/ml)
for 24 h.
Measurement of COX activity and protein expression
At the beginning of the experiment, cells were incubated
with a range of concentrations of aspirin, SC560, or
rofecoxib for 30 min before the addition of the calcium
ionophore A23187 (3105M) and incubation for a fur-
ther 30 min. Medium was then removed, and COX activity
over the incubation period was determined by measuring
the level of PGE2 within the medium using radioimmuno-
assay (11). COX protein expression was determined by
Western blot analysis using the same protocol and antibod-
ies as described previously for human (12) and mouse (13)
tissues. -Actin levels were estimated on blots previously
probed for COX-1 or COX-2 using a monoclonal primary
antibody raised to human -actin peptide, detected by a
secondary antibody to mouse immunoglobulin G (IgG)
raised in goat (Abcam, Cambridge, UK).
RESULTS
COX-1 predominates in murine airway and mediates
the prostaglandin brake to bronchoconstriction
Bronchi from wild-type mice contained predominantly
COX-1 immunoreactivity (Fig. 1; 87.29.6% of COX-1
positive control; n4). COX-1 immunoreactivity per-
sisted in tissue from COX-1/ mice (86.518.3% of
COX-1 positive control; n3), most likely explained by
the presence in tissue from these mice of a nonfunc-
tional protein product (7). No COX-2 immunoreactiv-
ity was detected in bronchi from either wild-type or
Figure 1. Western blot analysis of COX immunoreactivity in
mouse bronchi. Tissue extracts of mouse bronchi contained
immunoreactivity for COX-1 (A) with little or no detectable
COX-2 (B). Positive (ve) controls were extracts of MEG01
cells (22) for COX-1 and LPS-stimulated J774 cell extract (11)
for COX-2. Blots were subjected to immune staining for
-actin as an indicator of protein loaded. Lane 1, positive
control; lanes 2, 3, bronchi from wild-type mice; lanes 4, 5,
bronchi from COX-1/ mice. Similar results were obtained
using tissue from a total of 3 or 4 mice.
Figure 2. Comparison of bronchoconstriction induced by
U46619 (A) or acetylcholine (ACh; B) in airways from wild-
type (solid circles) or COX-1/ (open circles) mice. Data
are means  se; n  5 mice; 2-way ANOVA. ***P  0.001.
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COX-1/ mice (Fig. 1). Bronchi from wild-type or
COX-1/ mice contracted in response to increasing
concentrations of U46619 (109 to 3106 M; Fig. 2A)
or acetylcholine (108 to 3104M; Fig. 2B). For both
agonists, responses in bronchi from COX-1/ mice
were increased compared to those in bronchi taken
from wild-type mice. Pretreatment of bronchi from
wild-type animals with naproxen (104 M), diclofenac
Figure 3. Effect of NSAIDs on bronchoconstriction induced by U46619 (A–C) or ACh (D–F) in airway tissue from wild type mice.
The effects of the following NSAIDs were tested on constrictor responses to U46619 or ACh; naproxen (104 M), diclofenac
(105 M), and ibuprofen (105 M). Responses are means  se; n  4 or 5 experiments; 2-way ANOVA. ***P  0.001.
Figure 4. Effect of NSAIDs on bronchoconstrictions induced by U46619 (A–C) or ACh (D–F) in airway tissue from COX-1/
mice. The effects of the following NSAIDs were tested on constrictor responses to U46619 or ACh of naproxen (105 M),
diclofenac (105 M), and ibuprofen (104 M). Responses are means  se for n  4 or 5 experiments; 2-way ANOVA. ns,
nonsignficant difference (P0.05).
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(105 M), or ibuprofen (105 M) increased broncho-
constrictor responses to both U46619 (Fig. 3A–C) and
acetylcholine (Fig. 4A–C). In contrast, pretreatment of
bronchi from COX-1/ mice with ibuprofen or
naproxen had no significant effect on contractions
induced by either U46619 (Fig. 3D–F) or acetylcholine
(Fig. 4D–F).
Relation between COX-1 and COX-2 in nasal airway
tissue from aspirin-tolerant and aspirin-sensitive
patients
Similar to observations made with murine airway tis-
sues, cells cultured from nasal polyps obtained from
aspirin-sensitive or aspirin-tolerant patients contained
predominantly COX-1 protein. However, although in
limited amounts, COX-2 immunoreactivity was de-
tected in cells from both patient groups (Fig. 5A). In
contrast to some other types of human cells [e.g., A549
(12, 14), endothelial (15), vascular smooth muscle
(16)], the cytokine IL-1 did not induce increased
expression of COX-2 in nasal polyp cells (Fig. 5A). Cells
cultured from control and aspirin-sensitive individuals
released detectable levels of PGE2 over 24 h in culture
(Fig. 5B). There was no significant difference in abso-
lute levels of PGE2 released by cells from the two
patient groups cultured under control conditions (Fig.
5B). Despite having little or no effect on protein
expression, treatment of cells with IL-1 for 24 h
increased the release of PGE2. PGE2 release after IL-1
was significantly higher from cells cultured from aspirin-
sensitive than from aspirin-tolerant individuals (Fig. 5B).
Pharmacological characterization of COX isoforms
in nasal airway tissue from aspirin-tolerant
and aspirin-sensitive patients
COX activity in human cells cultured from aspirin-
sensitive and aspirin-tolerant individuals was inhibited
by aspirin (Fig. 6A) and the COX-1 selective inhibitor
SC560 (Fig. 6B). The potency and efficacy of aspirin
and SC560 was identical in cells cultured from the two
patient groups. In contrast to results with aspirin or
SC560, the COX-2-selective drug rofecoxib was inactive
as an inhibitor of PGE2 production in cells derived
from both aspirin-sensitive and aspirin-tolerant individ-
uals (Fig. 6C).
DISCUSSION
Asthma is a chronic inflammatory disease characterized
by inflammation of the airways and enhanced broncho-
constrictor responses. COX-1 and COX-2 are expressed
in the airways of patients with asthma. However, unlike
some other chronic inflammatory diseases, such as
arthritis, inhibition of COX with NSAIDs does not
provide any anti-inflammatory or analgesic relief in
asthma. In fact, for a subset of patients with asthma,
ingestion of NSAIDs induces asthma (aspirin-sensitive
responders). Paradoxically, while NSAIDs induce
asthma in sensitive individuals, selective COX-2 inhibi-
tors appear to be well tolerated (6).
In the current study, we confirm what is already
known about the effects of NSAIDs on airway responses
in tissue from wild-type mice. Pretreatment of bronchi
with NSAIDs consistently increased the bronchocon-
strictor effects of the thromboxane mimetic U46619 or
acetylcholine. NSAIDs increase bronchoconstrictor re-
sponses by two potential mechanisms, both of which
involve inhibition of prostaglandin synthesis. First,
prostaglandins produced by COX (including PGE2)
functionally antagonize airway contraction and sec-
ondly tonically suppress the synthesis and release of
Figure 5. Relative levels of COX-1 and COX-2 expressed in
human cells derived from control (no aspirin sensitivity) and
aspirin-sensitive donors and cultured under control condi-
tions or in the presence of IL-1 for 24 h. COX-1 and COX-2
immunoreactivity was detected in extracts from control cells
and those treated with IL-1 (	). Positive controls used for
this blot were MEG-01 cytosol, which contains only COX-1
(22), and A549 cells treated with IL-1, which express only
COX-2 (23). COX activity in cells measured by release of
PGE2 into the medium after incubation with A23187 (10
5 M)
for 30 min (B). Data are means  se; n  15 experiments
(cells from at least 3 different patients; experiments per-
formed in triplicate on at least 5 experimental days); 1-way
ANOVA with post hoc test. *P  0.05.
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bronchoconstrictor leukotrienes (17). NSAIDs inhibit
both COX-1 and COX-2; it is, therefore, not possible to
establish which isoform of COX predominates by the
use of NSAIDs alone. Here, we found that airway tissue
from laboratory mice contained predominantly COX-1,
with no detectable COX-2 expression. In line with this,
we found that the ability of NSAIDs to increase bron-
choconstrictor responses in mouse airways was com-
pletely lost in tissue from COX-1/ mice. Although
this observation may, on the face of it, seem predictable
from our studies on COX expression, it was essential to
check. Low levels of COX-2 may have been strategically
compartmentalized—and therefore difficult to detect
by Western blot analysis. Alternatively, NSAIDs may
have been affecting airway responses by non-COX-
dependent mechanisms known to be active in some
tissues (18). However, our data clearly and definitively
show that in mouse airways, COX-1, and not COX-2, is
the target for NSAID action. It is conceivable that
disruption of the COX-1 gene could influence COX-2
expression as a compensatory mechanism. However, as
in tissue from wild-type animals, we found no detect-
able COX-2 in airway samples from COX-1/ mice.
In human airway tissue cultured from nasal polyps,
we detected both COX-1 and COX-2. As was the case
for mouse tissue, COX-1 predominated. This was true
for tissue from non-aspirin-sensitive donors, as well as
from patients with aspirin-sensitive asthma. These ob-
servations are consistent with others in the literature
showing that both isoforms of COX are present in the
airways of patients with aspirin-sensitive asthma (5). In
our study, we went further, and investigated the func-
tional capacity of COX in human airway cells and the
COX isoform expressed. As expected, nasal polyp cells
released detectable levels of PGE2 when stimulated with
the calcium ionophore A23187. Interestingly, although
activation of cells with IL-1 did not induce COX-2 in
these cells, it did increase the production of PGE2 by
the cells. This was true for cells cultured from both
aspirin-sensitive and control subjects. Interestingly, af-
ter incubation with IL-1, cells derived from patients
with aspirin-sensitive asthma release higher levels of
PGE2 than cells cultured from control donors. Clearly,
this was not mediated by increased expression of COX
and most likely, therefore, was due to increased expres-
sion of phospholipase A2 (19), the enzyme responsible
for liberation of the substrate arachidonic acid.
In a previous study from our group using blood
donated by these patients, we found that COX-1 or
COX-2 was similarly inhibited by NSAIDs, including
aspirin, irrespective of aspirin sensitivity (9). In the
current study, we found that airway cells from aspirin-
sensitive and aspirin-tolerant donors were inhibited
similarly by aspirin or by SC560. Aspirin inhibits both
COX-1 and COX-2 (11, 20), whereas SC560 is a highly
selective inhibitor of COX-1 (21). Again, as with aspi-
rin, the potency and efficacy of SC560 were identical in
cells from aspirin-sensitive and control donors. Finally,
we found that, despite the presence of detectable levels
of COX-2, the COX-2-selective inhibitor rofecoxib, was
inactive as an inhibitor of COX in cells derived from
either aspirin-sensitive patients or control donors.
In summary, our findings using genetically modified
animals and tissue from aspirin-sensitive individuals
show that COX-1 is the dominant isoform in the
airways, particularly with regard to mechanical func-
tion. Notably, these data explain why aspirin and other
NSAIDs that inhibit COX-1, but not drugs that selec-
tively inhibit COX-2, can be tolerated by aspirin-sensi-
tive patients with asthma.
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